Treatment Outcome by Randomization
| . | Total . | TAD-TAD . | TAD-HAM . | P . |
|---|---|---|---|---|
| Patients randomized | 725 | 360 | 365 | |
| CR (%) | 68 (64-72) | 65 (59-70) | 71 (66-76) | .072 |
| Persistent leukemia (%) | 16 (13-19) | 17 (13-22) | 15 (11-20) | .491 |
| Early and hypoplastic death (%) | 16 (13-19) | 18 (14-23) | 14 (10-18) | .108 |
| Event-free survival | ||||
| Median (mo) | 9 (7.5-11.5) | 9 (6-12) | 10 (8-12) | .208 |
| 5 yrs (%) | 22 (18-26) | 19 (14-24) | 25 (19-30) | |
| Overall survival | ||||
| Median (mo) | 19 (15.5-24) | 18 (13.5-25) | 20 (14.5-25) | .338 |
| 5 yrs (%) | 31 (27-35) | 30 (24-36) | 32 (26-38) | |
| Patients with CR | 494 | 234 | 260 | |
| RFS | ||||
| Median (mo) | 20 (15-24) | 23 (16.5-30) | 18 (12-24) | .897 |
| 5 yrs (%) | 32 (27-37) | 29 (22-36) | 35 (28-42) | |
| Responders’ survival | ||||
| Median (mo) | 36 (29-47.5) | 38 (27.5-58.5) | 35 (25-49) | .640 |
| 5 yrs (%) | 42 (36-47) | 42 (34-50) | 41 (34-49) |
| . | Total . | TAD-TAD . | TAD-HAM . | P . |
|---|---|---|---|---|
| Patients randomized | 725 | 360 | 365 | |
| CR (%) | 68 (64-72) | 65 (59-70) | 71 (66-76) | .072 |
| Persistent leukemia (%) | 16 (13-19) | 17 (13-22) | 15 (11-20) | .491 |
| Early and hypoplastic death (%) | 16 (13-19) | 18 (14-23) | 14 (10-18) | .108 |
| Event-free survival | ||||
| Median (mo) | 9 (7.5-11.5) | 9 (6-12) | 10 (8-12) | .208 |
| 5 yrs (%) | 22 (18-26) | 19 (14-24) | 25 (19-30) | |
| Overall survival | ||||
| Median (mo) | 19 (15.5-24) | 18 (13.5-25) | 20 (14.5-25) | .338 |
| 5 yrs (%) | 31 (27-35) | 30 (24-36) | 32 (26-38) | |
| Patients with CR | 494 | 234 | 260 | |
| RFS | ||||
| Median (mo) | 20 (15-24) | 23 (16.5-30) | 18 (12-24) | .897 |
| 5 yrs (%) | 32 (27-37) | 29 (22-36) | 35 (28-42) | |
| Responders’ survival | ||||
| Median (mo) | 36 (29-47.5) | 38 (27.5-58.5) | 35 (25-49) | .640 |
| 5 yrs (%) | 42 (36-47) | 42 (34-50) | 41 (34-49) |
In parentheses are 95% CI.